Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) is a Healthcare company (Biotechnology) with a market capitalization of $1.9B. The Maz Rating grades it against the other companies in its sector.
Harmony Biosciences Holdings, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $32.80, Harmony Biosciences Holdings, Inc. trades at 10.6x trailing earnings, 1.9x sales and 1.8x book value, with an EV/EBITDA of 5.3. Over the last twelve months it generated about $991M of revenue and $181M of net income. It runs a gross margin of 74.0%, an operating margin of 22.2% and a net margin of 18.1%. It shows return on equity of 18.5%, return on invested capital of 13.7% and a free cash flow yield of 16.7%. On the balance sheet: a debt-to-equity ratio of 0.14 and a current ratio of 3.44. Over the past 52 weeks the share price ranged from $25.90 to $43.49, with a beta of 0.98.
Harmony Biosciences Holdings, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 8 Buy, 3 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.